Article
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip.
All News
Article
A multicenter study investigated the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients from multiple medical centers in China. The analysis focused on dose effects of HCQ on mortality.
Article
Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which were published in May, recommend universal CT chest screening for all asymptomatic patients with RA, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren’s disease.
Dr. John Cush
Tweet
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/2r9oS1Eb9k https://t.co/GqKq5E0bmp
Dr. John Cush
Tweet
Controversies in ILD
This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: https://t.co/ekP1Gg73yj
Mithu Maheswaranathan, MD
Tweet
🆕 Collaboration with @RheumNow 🔵
3-Part Series on #InterstitialLungDisease
Part2️⃣: Diagnosis & Subtypes of #ILD 🫁
👩🏻⚕️ What to look for on Physical Exam
🧪 Serologic Testing & Diagnostic Workup
🫁 Differentiating ILD Subtypes on Imaging
#RheumX #Pulmonology #MedTwitter #MedX https://t.co/X8cJVx2PCV
Dr. John Cush
Tweet
SARD-ILD: Significant diagnostic and treatment delays
Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease?
https://t.co/WyccifEHtY https://t.co/S6X5AhZCjz
Dr. John Cush
Tweet
Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club!
We’ll dive into two pivotal ILD studies:
📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025
📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet
Panelists: Dr. Toby Maher, Dr. Shervin Assassi
Moderator: https://t.co/l8EkX2hkLs
Dr. John Cush
Tweet
ILD and Mortality in Systemic Autoimmune Rheumatic Diseases
Dr. Bryant England, Lincoln, NE, discusses interstitial lung disease and mortality in systemic autoimmune rheumatic diseases (SARDs), as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month https://t.co/wtg9Te6oth
Dr. John Cush
Tweet
QD Clinic: Application of the ACR CHEST Guidelines to Two Cases
Dr. Sindhu Johnson, Toronto, discusses two cases that where the application of the ACR CHEST guidelines for the screening, monitoring and treatment of SSc-ILD and Rapidly Progressive ILD are applied, as part of https://t.co/ntW2WIvJ8c
Dr. John Cush
Tweet
Patient Resource: The Hidden Connection - ILD and Rheumatic Disease
Dr. Iazsmin Bauer Ventura, Chicago, talks about ILD as a window to systemic disease as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/8rJm4O3hHU
Dr. John Cush
Tweet
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortality. retrospective cohort study using the Mass General Brigham Biobank 221 RA-LD cases (151 RA-ILD, 70 RA-BR). RA-LD higher mortality (34 vs 13/1000PY; HR
Dr. John Cush
Tweet
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD
When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/qRoTr3r84x
Dr. John Cush
Tweet
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS or antifibrotics. 24% died, 7.5% transplant. Comorbidies were common; mean CCI 3.2; IPAF mortality worsened by
Dr. John Cush
Tweet
🆕 ILD (Part II): advanced insights
🫁 Multidisciplinary management
💊 Treatment strategies
📊 Prognosis & monitoring
🧑⚕️ What rheums should know next
⬇️ Download & learn more: https://t.co/dmhULfqiMj
Created by
@MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/ivvDjxkCvt
Dr. John Cush
Tweet
Non-Pharmacologic ILD Care
Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient care. Sponsored By: Boehringer Ingelheim
https://t.co/Mxg9P50m7C
#ILD #Rheumatology https://t.co/5wD1K7J1Gq
Dr. John Cush
Tweet
QD Clinic: Beyond the Numbers in Newly Diagnosed ILD
Dr. Eric Dein, Summit, NJ, presents a case of a new patient with interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/HLnX5WbbTw https://t.co/SZeI4bqSAm
Dr. John Cush
Tweet
How to assess ILD in your patients?
Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis. All patients with CTD may develop ILD but it is more common (% of patients with https://t.co/UXdvPJCqDi
sheila
Tweet
PsO/PsA patients have an ⬆️ CV risk brought about by traditional and CV risk factors.
Do you perform regular CV risk screening in your patients?
@RheumNow #APLAR25 https://t.co/BGNKrKeLsI
Dr. John Cush
Tweet
Target trial emulation looked at CV (MACE) events in 18,120 propensity score–matched adults with gout starting allopurinol who were given NSAIDs or colchicine for prophylaxis. MACE & CV death were signif. higher w/ NSAIDs vs Colchicine (HRs of 1.56 and 2.50), respectively. https://t.co/0T8slmPBng
